Boston Scientific Corp. last week announced that it has closed on its acquisition of Irvine-based medical device maker ...

On Friday, Boston Scientific Corporation (BSX) stock saw a decline, ending the day at $86.99 which represents a decrease of $-0.60 or -0.69% from the prior close of $87.59. The stock opened at $87.12 ...

Boston Scientific (BSX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Travis Steed ...

For valuable insights into Boston Scientific's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our ...

for stroke risk reduction in patients with non-valvular atrial fibrillation following a cardiac ablation were presented at ...

The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.

Spread the loveBoston Scientific, headquartered in Marlborough, has seen its stock surge by 50%, driven by a series of ...

Co-founded company that makes sacral neuromodulation device to treat patients with overactive bladder conditions.   IN THE ...

Cohen is retiring from Axonics following the close of its $3.7 billion sale to Boston Scientific Corporation (NYSE: BSX).

Boston Scientific (BSX) announced the close of its acquisition of Axonics (AXNX). The purchase price of $71 cash per share represents an ...

Boston Scientific announced the acquisition in January, but the review timeline dragged on after the Federal Trade Commission ...

Boston Scientific, a Marlborough medical device manufacturer, has officially closed its acquisition of Axonics Inc. after entering into a purchase agreement in January.